Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC
Status:
Completed
Trial end date:
2017-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether continuing erlotinib beyond disease
progression in combination with chemotherapy is beneficial for NSCLC patients who have EGFR
mutant disease or who have responded to EGFR TKI.